WO1996004375A1 - Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie - Google Patents
Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie Download PDFInfo
- Publication number
- WO1996004375A1 WO1996004375A1 PCT/EP1995/003043 EP9503043W WO9604375A1 WO 1996004375 A1 WO1996004375 A1 WO 1996004375A1 EP 9503043 W EP9503043 W EP 9503043W WO 9604375 A1 WO9604375 A1 WO 9604375A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteoclast
- osteoinductive
- retrovirus
- retroviruses
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention relates to the reduction in the unphysiological bone degradation caused by osteoclasts in osteoporosis and other skeletal changes characterized by bone loss.
- the bone matrix is subject to constant remodeling throughout life, with both the bone structure and the bone loss being regulated by numerous factors. Thereby the new formation of bone tissue by osteoblasts takes place, the breakdown of bone tissue by osteoclasts. Through an orderly regulation of these processes, regardless of the genetically programmed bone growth, the shape as well as the physical function of the bone and thus of the entire skeleton is preserved over several decades (skeletal homeostasis).
- a disadvantage of the process described in DE 44 11 718.3 is that the degradation of the natural bone substance is not prevented.
- This object is achieved according to the invention in that human or animal osteoblasts infected with an osteoinductive retrovirus are used for the production and isolation of one or more factors which can or can modulate the function of osteoclasts, the or the factors the infected osteoblast cells or from the cell culture supernatant of infected osteoblast cells can be isolated.
- the factor is one or more proteins that are encoded by the virus or induced by the virus in the cell. This protein or these proteins can be
- osteoblasts after an RFB retrovirus infection are no longer able to carry out osteoclast recruitment from undifferentiated progenitor cells and the formation of differentiated osteoclasts, that is to say the regeneration of bone-degrading cells.
- an inhibition of bone degradation likewise, and indirectly, to a constant Leads to an increase in the total amount of bone tissue and thereby ensures skeletal homeostasis in the case of beginning or already advanced osteoporosis.
- osteoblast-mediated signals provided they regulate osteoclast activity, are to be regarded as exocrine or paracrine factors.
- the bioactive molecules are therefore directly encoded by the virus or induced as a result of a viral infection of an osteoblast in the target cell and act either within a "microenvironment" or, distributed over the bloodstream, on target cells located further away.
- osteoinductive retroviruses leads to a reduction in osteoclast recruitment from precursor cells and / or a reduction in the biological activity of differentiated osteoclasts.
- the present invention is also achieved by other retroviruses which code for a polypeptide or several polypeptides with osteoclast-modulating activities or induce corresponding factors in the target cell.
- osteoclast-modulating activities relates to the maintenance of skeletal homeostasis in situations in which there is otherwise an increased breakdown of bone tissue due to increased osteoclast activity or a steady increase in bone tissue is observed.
- new bone formation means the general increase in the trabecular thickness in the bone cancellous bone of tubular bones and vertebral bodies, the increase and strengthening of the bone shaft in the diaphyseal and metaphyseal area of long tubular bones and the local new bone formation in the entire skeletal area .
- Retroviruses with osteoinductive properties were isolated: - Retroviruses cloned directly from the mouse genome (Murray et al.
- the RFB retrovirus preferably in the molecular cloned form (RFB-14), is preferably used, produced by the cell line RFB MBK 6a (DSM ACC 2146).
- these viruses induce bone changes such as osteopetrosis and osteomas and, to a different extent, lymphomas after injection into newborn mice, depending on the mouse test strain.
- the RFB virus has the strongest biological activity of these retroviruses on skeletal cells. In the CBA test strain, no lymphoma formation was detectable eight months after infection with the RFB virus, while at this point multiple osteomas had already developed in over 50% of the mice.
- osteoinductive retroviruses can be used to develop a therapeutic agent for the treatment of degenerative bone diseases.
- Osteopetrosis is characterized by a thickening of the bone shaft in the area of long tubular bones and a focal or generalized thickening of the trabeculae in the spongiosa area of the vertebral bodies. In more pronounced forms, complete loss of the bone marrow cavity and replacement of bone marrow by compact bone tissue can occur. In these cases, massive growth of bone tissue on the trabeculae in the cancellous area of the vertebral bodies leads to complete loss of the cancellous bone structure and to the formation of a solid, "petrosed” bone (AB Murray, J. Schmidt, A. Luz Osteopetrosis induced by retrovirus , mouse. In: Cardiovascular and Musculoskeletal Systems, TC Jones, U. Mohr, RD Hunt (Eds.) Springer, 1991).
- osteoclast-modulating factor produced or induced by osteoblasts infected with osteoinductive retroviruses acts on osteoclast precursor cells and on osteoclasts and can be used to develop a medicament for the therapy of osteoporosis.
- Figure 1 shows the induction of multinuclear, TRAP-positive cells after treatment of spleen cells with 1,25 (OH) 2 vitamin D 3 and various retroviruses.
- Osteoclasts are derived from hematopoietic stem cells (Hattersley and Chambers, J. Cell Physiol. 140: 478-482, 1989; Haganaars et al., Bone Miner. 6: 187-190, 1989).
- the induction of osteoclasts from stem cells takes place through cellular alternating Effects due to cell-cell contact between hematopoietic progenitor cells and stromal cells (Takahashi et al., Endocrinology 123: 2600-2602, 1988).
- Osteoclast-inductive stromal cells are found primarily in the bone marrow, with osteoclast precursor cells found in the bone marrow and spleen.
- Osteopetrosis is characterized by a thickening of the bone shaft in the region of long tubular bones and a thickening of the bone trabeculae in the cancellous region of the vertebral bodies. In more pronounced forms, there can be complete loss of the bone marrow cavity and replacement of bone marrow with compact bone tissue.
- osteopetrosis as a result of a retrovirus infection can be seen on the one hand as a direct result of an infection of osteoblasts and subsequent continuous, increased matrix protein formation (Schmidt et al., Am J.
- Pathol. 129 503-510, 1987; Livne et al., Calcif. Tissue int. 44: 25-35, 1989).
- a disruption of skeletal homeostasis with continuous bone growth can also result from a reduction in the total number of osteoclasts in the skeleton and thus from a resulting reduced bone resorption.
- the RFB virus and other osteoinductive retroviruses are able to significantly reduce the induction of osteoclasts, which in turn leads to an increase in new bone formation.
- This result was extremely surprising since the entire literature and in particular DE 44 11 718.3 exclusively describe the bone-inducing properties of osteoinductive retroviruses, in particular the RFB retrovirus, by stimulating the bone-regenerating activity of the osteoblasts.
- the present invention is also for the development of a therapeutic agent for the treatment of e.g. age-related bone loss can be used.
- This step is surprising and unexpected in that these viruses are pathogenic in the infected mice and not only the changes in the lymphatic but also in the bone-forming system are of an unphysiological, pathogenic nature.
- the infected cell or the supernatant, ie the nutrient medium becomes RFB virus-infected osteo- blast progenitor cells with a stromal cell character, a factor, namely a protein, which has osteoclast-modulating activities.
- This factor is induced by the RFB virus.
- a continuously growing cell line (RFB MBK 6a) containing the RFB-14 provirus genome was deposited with the DSM on August 18, 1993 and received the access number DSM ACC2146 (cf. DE 44 11 718.3).
- the RFB retrovirus is therefore preferably used, particularly preferably in its molecularly cloned form as RFB-14.
- RFB-14 the molecularly cloned form
- other osteoinductive retroviruses can also be used, which are characterized in more detail above in the description.
- the DNA or RNA of these osteoinductive retroviruses is preferably used, either in their complete sequence or in the form of a partial sequence thereof, these sequences preferably being present in a suitable vector system.
- the nature of the osteoclast-modulating factor is still unknown, although it is almost certainly a protein or several poreins.
- the osteoclast-modulating factor is either encoded by the osteoinductive retrovirus or induced by this in the cell.
- the DNA or RNA of the osteoinductive retroviruses thus code for an osteoclast-modulating factor or induce it. Partial sequences of the DNA or the RNA of the osteoinductive retroviruses are preferably used, which code for or induce the osteoclast-modulating factor.
- DNA or RNA hybridizing therewith, preferably under stringent conditions, can also be used.
- spleen tissue of young mice For the experimental detection of the induction of osteoclast recruitment and the reduction of osteoclast induction from undifferentiated progenitor cells by retroviruses, cell cultures from spleen tissue of young mice are used. For this purpose, a single cell suspension is made from the spleen. These spleen cells are cultivated in a number of 5 ⁇ 10 5 cells per well together with 4x10 * osteoblasts in multi-well plates (96 wells per plate). The osteoblasts come from the bony skull roof of newborn mice, from which a single cell population was produced by fractional enzymatic digestion of the tissue. To reduce osteoclast recruitment, the osteoblasts intended for cocultivation are infected with RFB virus or other retroviruses.
- the cells are washed twice with buffered saline and fixed with 3% formalin solution, after which a substrate solution to which tartrate has been added is added to the cells.
- the expression of the calcitonin receptor is a specific feature of osteoclasts. After approximately 30-60 minutes of exposure to the substrate solution, mononuclear and multinucleated cells stain. The former represent osteoclast precursor cells, the latter represent osteoclasts.
- the respective number of stained cells are quantitatively determined.
- the experiments are carried out for statistical validation in a 4-fold parallel approach.
- the number of stained cells provides a measure of the osteoclast recruitment activity of the osteoblast population used or of the effect of the retrovirus infection of the osteoblasts on the reduction of the osteoclast recruitment activity.
- Table 1 shows the induction of mononuclear (osteoclast precursors) and multinuclear (osteoclasts), TRAP (tartrate-resistant, acid phosphatase, an osteoclast marker) - positive cells after treatment of spleen cells with 1.25 (OH) 2 Vitamin D 3 and RFB virus.
- the treatment shows a significant reduction in osteoclast precursors (p ⁇ 0.005) and osteoclasts (p ⁇ 0.05) recruitment in two independent experiments.
- Figure 1 shows the induction of multinuclear (osteoclasts), TRAP-positive cells after treatment of spleen cells with 1.25 (OH) 2 vitamin D 3 and various retroviruses.
- A control group, 1.25 (OH ) 2 vitamin D 3 treatment;
- Biological activity is defined by the steady increase in bone tissue in infected mice.
- Treatment of the cells in the in vitro experiment shows a slight reduction in osteoclast recruitment with ⁇ 0TS-25-G18 (p ⁇ 0.05) and a strong reduction in osteoclast recruitment with RFB virus (p ⁇ 0.005) .
- the method according to the invention is particularly well suited for the reduction of osteoclast recruitment from progenitor cells and thus for a reduction in bone resorption.
- Cloned retrovirus genomes, in particular the RFB provirus genome, as well as the partial sequences of retrovirus genomes responsible for its biological effectiveness, in particular the RFB pro virus genome or related hybridizing sequences can also be used for somatic gene therapy. These are preferably sequences which hybridize under stringent conditions or partial sequences thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32239/95A AU3223995A (en) | 1994-08-01 | 1995-07-31 | Retrovirus-induced osteoclast modulation for osteoporosis therapy |
EP95928500A EP0775207A1 (de) | 1994-08-01 | 1995-07-31 | Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19944427221 DE4427221A1 (de) | 1994-08-01 | 1994-08-01 | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
DEP4427221.9 | 1994-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004375A1 true WO1996004375A1 (de) | 1996-02-15 |
Family
ID=6524659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/003043 WO1996004375A1 (de) | 1994-08-01 | 1995-07-31 | Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0775207A1 (de) |
AU (1) | AU3223995A (de) |
DE (1) | DE4427221A1 (de) |
WO (1) | WO1996004375A1 (de) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038707A1 (en) * | 1998-12-24 | 2000-07-06 | Garvan Institute Of Medical Research | Method for the treatment of bone loss |
KR100496409B1 (ko) * | 1997-03-05 | 2005-09-08 | 료세이덴소 가부시키가이샤 | 코넥터 |
US8637643B2 (en) | 2005-05-03 | 2014-01-28 | Ucb Pharma, S.A. | Sclerostin binding antibody |
US8986685B2 (en) | 1998-11-27 | 2015-03-24 | Ucb Pharma S.A. | Compositions and methods for increasing bone mineralization |
US9089553B2 (en) | 2005-05-03 | 2015-07-28 | Amgen Inc. | Method for inhibiting bone resorption |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
US9145457B2 (en) | 2011-03-25 | 2015-09-29 | Amgen Inc. | Sclerostin antibody crystals and formulations thereof |
US9352043B2 (en) | 2010-05-14 | 2016-05-31 | Amgen Inc. | High concentration antibody formulations |
US9657090B2 (en) | 2011-12-28 | 2017-05-23 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
US9822173B2 (en) | 2012-11-21 | 2017-11-21 | Amgen Inc. | Heterodimeric immunoglobulins |
US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
US10538584B2 (en) | 2011-08-04 | 2020-01-21 | Amgen Inc. | Methods for treating bone gap defects |
US11466079B2 (en) | 2018-03-30 | 2022-10-11 | Amgen Inc. | C-terminal antibody variants |
US11576970B2 (en) | 2016-03-10 | 2023-02-14 | UCB Biopharma SRL | Pharmaceutical formulations |
US11851483B2 (en) | 2014-12-12 | 2023-12-26 | Amgen Inc. | Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001827A1 (en) * | 1991-07-23 | 1993-02-04 | Osteosa Inc. | Osteoclast growth regulatory factor |
WO1993005751A2 (en) * | 1991-08-30 | 1993-04-01 | Creative Biomolecules, Inc. | Osteogenic proteins in the treatment of bone deseases |
WO1995027063A2 (de) * | 1994-04-05 | 1995-10-12 | Gsf Forschungszentrum Umwelt | Rfb-retrovirusgenom |
-
1994
- 1994-08-01 DE DE19944427221 patent/DE4427221A1/de not_active Withdrawn
-
1995
- 1995-07-31 EP EP95928500A patent/EP0775207A1/de not_active Withdrawn
- 1995-07-31 WO PCT/EP1995/003043 patent/WO1996004375A1/de not_active Application Discontinuation
- 1995-07-31 AU AU32239/95A patent/AU3223995A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001827A1 (en) * | 1991-07-23 | 1993-02-04 | Osteosa Inc. | Osteoclast growth regulatory factor |
WO1993005751A2 (en) * | 1991-08-30 | 1993-04-01 | Creative Biomolecules, Inc. | Osteogenic proteins in the treatment of bone deseases |
WO1995027063A2 (de) * | 1994-04-05 | 1995-10-12 | Gsf Forschungszentrum Umwelt | Rfb-retrovirusgenom |
Non-Patent Citations (2)
Title |
---|
A. MURRAY ET AL.: "Retrovirus-induced osteoporosis in mice.", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 124, no. 2, HAGERSTOWN, MD, USA, pages 319 - 323 * |
L. PEDERSEN ET AL.: "Molecular cloning of osteoma-inducing replication-competent murine leukemia viruses from the RFB osteoma virus stock.", JOURNAL OF VIROLOGY, vol. 66, no. 10, BALTIMORE, MD, USA, pages 6186 - 6190 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496409B1 (ko) * | 1997-03-05 | 2005-09-08 | 료세이덴소 가부시키가이샤 | 코넥터 |
US9791462B2 (en) | 1998-11-27 | 2017-10-17 | Ucb Pharma, S.A. | Compositions and methods for increasing bone mineralization |
US8986685B2 (en) | 1998-11-27 | 2015-03-24 | Ucb Pharma S.A. | Compositions and methods for increasing bone mineralization |
WO2000038707A1 (en) * | 1998-12-24 | 2000-07-06 | Garvan Institute Of Medical Research | Method for the treatment of bone loss |
US11939372B2 (en) | 2005-05-03 | 2024-03-26 | Amgen Inc. | Binding agents |
US9296812B2 (en) | 2005-05-03 | 2016-03-29 | Amgen Inc. | Sclerostin binding antibodies |
US9089553B2 (en) | 2005-05-03 | 2015-07-28 | Amgen Inc. | Method for inhibiting bone resorption |
US10562964B2 (en) | 2005-05-03 | 2020-02-18 | Amgen Inc. | Methods for isolating antibodies that bind sclerostin |
US10273293B2 (en) | 2005-05-03 | 2019-04-30 | Amgen Inc. | Method for inhibiting bone resorption |
US8637643B2 (en) | 2005-05-03 | 2014-01-28 | Ucb Pharma, S.A. | Sclerostin binding antibody |
US11091537B2 (en) | 2007-09-17 | 2021-08-17 | Amgen Inc. | Method for inhibiting bone resorption |
US10064946B2 (en) | 2010-05-14 | 2018-09-04 | Amgen Inc. | High concentration antibody formulations |
US9352043B2 (en) | 2010-05-14 | 2016-05-31 | Amgen Inc. | High concentration antibody formulations |
US11040102B2 (en) | 2010-05-14 | 2021-06-22 | Amgen Inc. | High concentration antibody formulations |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
US9920114B2 (en) | 2011-03-25 | 2018-03-20 | Amgen Inc. | Antibody formulations |
US9145457B2 (en) | 2011-03-25 | 2015-09-29 | Amgen Inc. | Sclerostin antibody crystals and formulations thereof |
US9617333B2 (en) | 2011-03-25 | 2017-04-11 | Amgen Inc. | Sclerostin antibody crystals and formulations thereof |
US10538584B2 (en) | 2011-08-04 | 2020-01-21 | Amgen Inc. | Methods for treating bone gap defects |
US9657090B2 (en) | 2011-12-28 | 2017-05-23 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
US9913900B2 (en) | 2011-12-28 | 2018-03-13 | Amgen Inc. | Method of treating alvelor bone loss through the use of anti-sclerostin antibodies |
US10799583B2 (en) | 2012-07-05 | 2020-10-13 | Ucb Pharma, S.A. | Treatment for bone diseases |
US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
US11896667B2 (en) | 2012-07-05 | 2024-02-13 | Ucb Pharma S.A. | Treatment for bone diseases |
US9822173B2 (en) | 2012-11-21 | 2017-11-21 | Amgen Inc. | Heterodimeric immunoglobulins |
US11466078B2 (en) | 2012-11-21 | 2022-10-11 | Amgen Inc. | Heterodimeric immunoglobulins |
US10233237B2 (en) | 2012-11-21 | 2019-03-19 | Amgen Inc. | Heterodimeric immunoglobulins |
US11851483B2 (en) | 2014-12-12 | 2023-12-26 | Amgen Inc. | Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen |
US11576970B2 (en) | 2016-03-10 | 2023-02-14 | UCB Biopharma SRL | Pharmaceutical formulations |
US11466079B2 (en) | 2018-03-30 | 2022-10-11 | Amgen Inc. | C-terminal antibody variants |
US11858983B2 (en) | 2018-03-30 | 2024-01-02 | Amgen Inc. | C-terminal anti-sclerostin antibody variants |
Also Published As
Publication number | Publication date |
---|---|
AU3223995A (en) | 1996-03-04 |
EP0775207A1 (de) | 1997-05-28 |
DE4427221A1 (de) | 1996-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996004375A1 (de) | Retrovirus-induzierte osteoklasten-modulation für die osteoporose-therapie | |
KR101930718B1 (ko) | 불사화 줄기세포 및 그 생산물을 유효 성분으로 하는 의약 조성물 및 의약 제제 | |
DE69922933T2 (de) | Anwendungen für humane nicht autologe, mesenchymale stammzellen | |
DE69435096T2 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
US20060247195A1 (en) | Method of altering cell properties by administering rna | |
DE01201555T1 (de) | Biosynthetische osteogene Proteine und solche enthaltende osteogene Einrichtungen | |
DE69231250T2 (de) | Kombinierte zelluläre und immunsuppressive therapien | |
Yu et al. | Human nail bed extracellular matrix facilitates bone regeneration via macrophage polarization mediated by the JAK2/STAT3 pathway | |
WO2016089252A1 (en) | Stem cell material and method of manufacturing | |
JP6410343B2 (ja) | 脂肪組織由来幹細胞から表皮角化細胞への誘導 | |
WO1998030234A1 (en) | Compositions for osteogenesis and chondrogenesis | |
DE69832880T2 (de) | Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen | |
Heggeness et al. | Quiescent pluripotent stem cells reside within murine peripheral nerves that can be stimulated to proliferate by recombinant human bone morphogenic protein 2 or by nerve trauma | |
Ahuja et al. | Botanicals and oral stem cell mediated regeneration: a paradigm shift from artificial to biological replacement | |
EP1337625B1 (de) | Stammzellen, verfahren zu deren expansion in vitro sowie deren verwendung | |
DE102008036060A1 (de) | Zellbasiertes Verfahren und Mittel zum Knochenaufbau | |
EP0957944B1 (de) | Knochenmatrix, deren verwendung, therapeutische zubereitung und kit | |
KR102286634B1 (ko) | 꾸지뽕나무 열매 추출물을 포함하는 줄기세포의 골분화 촉진용 조성물 | |
CN111662876B (zh) | 一种诱导人成纤维细胞重编程为Leydig样细胞的方法 | |
DE19918446A1 (de) | Verwendung von Coxsackievirus B3 zur Verbesserung der Transfektion von Zellen | |
DE102006020307A1 (de) | TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung | |
DE102009053519B4 (de) | Verfahren zur Gewinnung von Myofibroblasten zur Herstellung von zur Transplantation geeignetem Gewebe | |
Schmitt | The influence of the electromagnetic field on the activity of alkaline phosphatase in immobilised children | |
Radford | Differentiation of mesenchymal stem cells to tendon-like progenitor cells via growth factor stimulation | |
Seidel et al. | Studies on the resistance of the C 57 Bl/6 mouse strain to the polycythemia-inducing strain of the Friend virus (FV-P) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995928500 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 776551 Date of ref document: 19970418 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1995928500 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995928500 Country of ref document: EP |